Corcept Therapeutics Inc

CORTNASDAQ · USD
63.62USD0.00 (-2.10%)
699

Corcept Therapeutics Inc (CORT) Covered Calls

Corcept Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 94.05%, high versus the past year. CORT's highest covered call setup is the $70.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 7.73% out of the money with 1 day to expiration, a 7.80% return until expiration, and a 2,847.88% theoretical annualized return. Across the setups shown, annualized returns run from 282.53% to 2,847.88% at strikes between $70.00 and $100.00, with 1 to 57 days to expiration, as of Nov 19, 2026.

Read more

Running CORT covered calls helps you generate income from Corcept Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CORT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CORT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CORT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CORT covered call is worth writing.

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.

2026-11-20170.007.730.052.10507.007.802847.88-0.08+0.26512.05
2026-12-1829100.0053.890.501.403552.0054.66688.00-0.77+0.11700.90
2026-12-182995.0046.200.301.753032.0046.66587.28-0.46+0.121,5001.45
2026-12-182990.0038.500.052.802507.0038.58485.59-0.08+0.161,5422.75
2026-12-182985.0030.812.003.602202.0033.89426.51-3.08+0.26991.60
2027-01-1557100.0053.891.103.503612.0055.59355.95-1.69+0.192172.40
2027-01-155797.5050.050.603.703312.0050.97326.38-0.92+0.19223.10
2026-12-182980.0023.111.804.701682.0025.88325.79-2.77+0.301382.90
2027-01-155795.0046.200.853.203087.0047.51304.21-1.31+0.191752.35
2027-01-155792.5042.351.154.102867.0044.12282.53-1.77+0.22112.95

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank94.05% High
  • Market cap (M$)6,963
  • 52 weeks high-49.66%
  • 52 weeks low121.98%
  • Analyst recommendationBuy
    1.67
  • Target price$142.60
    124.14% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-03
  • P/E50.21
  • Future P/E13.23
  • EPS (ttm)1.27
  • EPS growth next 5 years110.90%

As of Nov 20, 2026